News

AMD is heading into earnings with two positive catalysts: strong server chip demand (driven by AI and cloud infrastructure buildout) and momentum from its new rack-scale computing products. This matters because AMD is a key player in the semiconductor space where competitive gains translate to margin expansion and market share wins. For Australian investors, strength in semiconductor names like AMD can lift tech-heavy portfolios and reflects broader demand for AI-related infrastructure globally—a trend that's supporting the Nasdaq and indirectly benefiting Australian tech exporters.

Marriott delivered mixed Q2 results with RevPAR (revenue per available room) growing 3.4%, a key metric for hotel operators showing modest pricing power despite inflationary pressures. The company offset softer Q3 guidance with an upbeat FY26 earnings outlook, suggesting management expects demand recovery in the near-to-medium term. For Australian investors, this signals cautious optimism in global travel demand—important for ASX-listed hospitality plays like Crown Resorts and Qantas—though the weak near-term guidance warrants attention to booking trends.

Black Bear Minerals has released positive scoping study results for its Independence project, showing a post-tax NPV of $511M at a 5% discount rate and a 64% internal rate of return. These metrics suggest a potentially viable mining project with strong economic returns, which typically supports junior explorer valuations. Australian investors should note this is an early-stage feasibility study; actual project execution, permitting timelines, and commodity price assumptions will determine whether these returns materialise.

AstraZeneca and Bristol Myers Squibb held merger discussions according to Financial Times reporting, though the talks appear to have not progressed. A pharma mega-merger of this scale would reshape the industry landscape and create significant shareholder value implications for both companies. Australian investors should monitor further developments, as such consolidation typically affects drug pricing, R&D pipelines, and healthcare sector valuations globally—with potential flow-on effects for ASX healthcare stocks and superannuation holdings in pharma exposure.

Amazon reported outsized earnings growth driven partly by unrealised gains on its Anthropic investment rather than core business performance—a trend now visible across Big Tech. This reflects how concentrated S&P 500 gains have become: a handful of mega-cap tech stocks are inflating headline earnings through investment portfolios and AI-related valuations, not necessarily underlying operational strength. For Australian investors, this matters because US equity indices are heavily weighted to these names; understanding what's driving reported profits (paper gains vs. actual revenue growth) is crucial before chasing US market rallies.

Apple's earnings disappointed under Tim Cook's final results announcement as CEO, sending shares lower, while Microsoft's results outperformed in what appears to be a mixed earnings week for big tech. This matters because Apple and Microsoft are massive constituents of global indices and their divergent performance signals selective weakness in the mega-cap tech space—investors are being more discerning about growth narratives. Australian investors with exposure to tech ETFs should monitor these trends; Apple and Microsoft are major holdings in most ASX-listed tech funds, and mixed earnings from titans can signal broader tech sector caution heading into 2025.

27 out of 29 industrial companies beat earnings-per-share expectations, signalling broad-based strength in the industrial sector. This high beat rate suggests companies are managing costs effectively and potentially benefiting from pricing power or operational efficiency gains. For Australian investors, this is relevant given our exposure to industrials through the ASX 200; however, without detail on which companies, the magnitude of beats, or forward guidance, the market impact appears contained to sector-specific investors.

A strong earnings season is unfolding with 84% of S&P 500 companies beating EPS expectations and 72% delivering year-on-year profit growth—both robust metrics that support the recent equity rally. This broad-based earnings strength suggests the US economy remains resilient despite recession fears and sticky inflation, which could reinforce the Fed's 'higher for longer' stance on interest rates. For Australian investors, strong US corporate earnings typically support global risk appetite and commodity demand, benefiting ASX sectors like materials and energy, though the persistent interest rate environment could weigh on domestic rate-sensitive stocks.

US financial stocks fell during earnings season, with Goldman Sachs and Robinhood among notable decliners, while European banks and Marktaxess (MKTX) gained. This mixed performance reflects divergent earnings trajectories across the financial sector, with some firms navigating margin pressures and trading volatility better than others. For Australian investors, this signals uneven health in global financial services—watch for how local banks' earnings compare when they report, and monitor whether capital market conditions favour Australian brokers and fintech players.

Fortescue reported record earnings but flagged a $747m writedown, likely related to its Iron Bridge magnetite project expansion. This mixed signal—strong operational performance offset by a significant asset impairment—suggests the company is facing project headwinds or cost pressures on major capital expenditure. For ASX investors, this highlights execution risks in mining capex cycles and the importance of looking past headline earnings to understand underlying operational health, especially as commodity prices remain volatile.

Monadelphous Group's Kerman Contracting has secured a $165M design and construction contract from Rio Tinto, a significant win that should provide revenue visibility and support earnings growth for the ASX-listed engineering services provider. This contract demonstrates continued demand for infrastructure work in mining and positions MND well in the resources sector recovery cycle. Australian investors should monitor MND's project execution and margin profile—major contract wins like this can be earnings-accretive if delivered efficiently, but project risks and cost overruns are key execution risks to watch.

Apple has warned of upcoming supply constraints that will limit sales of its core products—Mac, iPhone, and iPad—sending shares lower. This suggests the company expects revenue headwinds in coming quarters due to manufacturing or logistics bottlenecks, likely driven by ongoing supply chain disruptions or demand shifts. For Australian investors, this is significant because Apple is a major ASX holding via tech-heavy index funds and ETFs; a weaker earnings outlook could weigh on the broader tech sector and the ASX 200.

Roblox has cut its Q3 bookings guidance following a Q2 earnings miss, signalling weakness in user engagement or monetisation on its platform. This matters because Roblox is a bellwether for the health of the metaverse and user-generated content gaming space—its struggles suggest softer demand for digital entertainment post-pandemic normalisation. Australian investors with exposure to US tech or gaming ETFs should monitor whether this reflects broader softening in the sector or is company-specific; watch upcoming tech earnings for confirmation of trends.

Microsoft's earnings beat and guidance for continued AI spending is lifting semiconductor stocks, particularly memory and storage chipmakers like Micron and SanDisk who supply components for AI infrastructure. This signals sustained demand for chip hardware as big tech firms race to build out AI capabilities—good news for semiconductor suppliers globally. Australian investors should watch how this translates to ASX tech stocks and whether it sustains the recent rally in semiconductor-exposed companies on the local bourse.

AbbVie's upcoming earnings report will be closely watched as the company navigates the ongoing decline of Humira (its blockbuster arthritis drug) following patent expiry and biosimilar competition. The focus shifts to whether the company's immunology portfolio can offset these losses and drive future growth. For Australian investors, this matters because AbbVie is a major healthcare holding in ASX-listed funds, and any earnings surprise could influence healthcare sector performance and pharmaceutical stock valuations more broadly.

Meta is facing investor skepticism over rising AI capex without clear near-term monetisation pathways beyond its core advertising business. This reflects a broader market concern about mega-cap tech spending on AI infrastructure while profitability questions linger. For Australian investors, Meta's weakness matters: the company dominates digital ad spend in Australia, and confidence shocks here can ripple through local marketing budgets and ad-tech-dependent businesses listed on the ASX.

Mastercard delivered solid Q2 earnings with 14% revenue growth and 10% purchase volume expansion, signalling continued strength in consumer spending and digital payments adoption globally. The company's forward guidance will be key—if it suggests sustained momentum despite inflation pressures, it could reinforce positive sentiment around payment processors and fintech exposure. For Australian investors, this matters because it reflects global consumer resilience and validates the long-term shift to cashless transactions; watch whether management commentary addresses macro headwinds or shows confidence in sustained spending demand.

Mastercard delivered better-than-expected Q2 results, signalling resilient consumer spending and strong demand for digital payment solutions. This is a positive signal for global consumer health and digital transformation trends, though the impact is primarily confined to the payments sector rather than broader markets. Australian investors should note implications for local fintech and payment stocks, plus ASX-listed banks' payment processing volumes.

Rolls-Royce and BAE Systems upgraded profit guidance after governments globally committed to higher defence spending, with Rolls-Royce shares rising 5.5%. This reflects a structural shift in government budgets—driven by geopolitical tensions (Russia, China, Middle East)—that benefits major defence contractors. For Australian investors, this is worth watching as ASX-listed defence suppliers like Northrop Grumman partnerships and local contractors may see flow-on opportunities, though the direct exposure to these UK-listed giants is limited for most retail investors. The broader trend suggests defence will outperform cyclical sectors in coming years.

Lloyds Banking Group announced a £2bn cost-cutting program over four years, backed by £13bn in technology and AI investments through 2030. While efficiency gains and shareholder returns sound positive, the lack of detail on job losses creates uncertainty—cost cuts of this scale typically involve redundancies, which could draw regulatory scrutiny in the UK. For Australian investors, this signals how major international banks are pivoting to AI-driven models; watch whether the strategy actually improves profitability or merely redirects costs, and monitor ASX-listed bank responses (CBA, ANZ, Westpac) for similar announcements.